Plan B, FDA Acting Commissioner Used To Spotlight Conflict-Of-Interest Bill
Executive Summary
Rep. Henry Waxman (D-Calif.) is highlighting the escalating controversy surrounding the proposed OTC switch of Plan B to build support for a bill intended to limit the politicization of scientific decisions